T1	intervention 71 80	goserelin
T2	eligibility 513 573	Pre-menopausal women with ER-positive advanced breast cancer
T4	control 624 641	monthly goserelin
T5	outcome-Measure 734 782	progression-free survival (PFS) rate at 24 weeks
T7	total-participants 1025 1028	222
T8	intervention-participants 1078 1081	109
T9	control-participants 1105 1108	113
T10	outcome 1111 1119	PFS rate
T11	iv-bin-percent 1135 1141	61.5 %
T12	cv-bin-percent 1166 1172	60.2 %
T14	iv-bin-percent 1337 1343	23.9 %
T15	cv-bin-percent 1368 1374	26.9 %
T16	outcome 1463 1491	mean serum E2 concentrations
T17	iv-cont-mean 1559 1569	20.3 pg/mL
T18	cv-cont-mean 1574 1584	24.8 pg/mL
T3	outcome 1120 1130	at week 24
T13	outcome 1329 1332	ORR
T6	outcome-Measure 941 970	objective response rate (ORR)
T19	outcome-Measure 972 987	serum E2 levels
T20	outcome-Measure 989 995	safety
T21	outcome-Measure 1001 1013	tolerability
